ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance - GlobeNewswire

ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance  GlobeNewswire

YONKERS, N.Y., Aug. 28, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the ...



Comments

Popular posts from this blog

Urinary Tract Infection (UTI): Causes, Symptoms & Treatment - Cleveland Clinic

Rashes that look like scabies: Causes, symptoms, and treatment - Medical News Today